Summary
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
In our report, we only study four approved PARPi (Lynparza, Zejula, Rubraca and Talzenna). One unit is one tablet or one capsule.
According to APO Research, The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for PARP (Poly ADP-Ribose Polymerase) Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for PARP (Poly ADP-Ribose Polymerase) Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for PARP (Poly ADP-Ribose Polymerase) Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for PARP (Poly ADP-Ribose Polymerase) Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor include AstraZeneca, Tesaro, Merck & Co, Clovis Oncology, Pfizer, GSK and Zai Lab, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for PARP (Poly ADP-Ribose Polymerase) Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for PARP (Poly ADP-Ribose Polymerase) Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PARP (Poly ADP-Ribose Polymerase) Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for PARP (Poly ADP-Ribose Polymerase) Inhibitor sales, projected growth trends, production technology, application and end-user industry.
PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Company
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
GSK
Zai Lab
PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Type
Lynparza
Zejula
Rubraca
Talzenna
Other
PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Application
Ovarian Cancer
Breast Cancer
Other
PARP (Poly ADP-Ribose Polymerase) Inhibitor Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PARP (Poly ADP-Ribose Polymerase) Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PARP (Poly ADP-Ribose Polymerase) Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the PARP (Poly ADP-Ribose Polymerase) Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PARP (Poly ADP-Ribose Polymerase) Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of PARP (Poly ADP-Ribose Polymerase) Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of PARP (Poly ADP-Ribose Polymerase) Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
- Market Overview
- Product Definition
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size, 2020 VS 2024 VS 2031
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Estimates and Forecasts (2020-2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Estimates and Forecasts (2020-2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Average Price (2020-2031)
- Assumptions and Limitations
- Study Goals and Objectives
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Dynamics
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Drivers
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Opportunities and Challenges
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Restraints
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Manufacturers
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers (2020-2025)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers (2020-2025)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Sales Price by Manufacturers (2020-2025)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers, Product Type & Application
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Establishment Date
- Market Competitive Analysis
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market CR5 and HHI
- Global Top 5 and 10 PARP (Poly ADP-Ribose Polymerase) Inhibitor Players Market Share by Revenue in 2024
- 2024 PARP (Poly ADP-Ribose Polymerase) Inhibitor Tier 1, Tier 2, and Tier 3
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Type
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Type Introduction
- Lynparza
- Zejula
- Rubraca
- Talzenna
- Other
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020 VS 2024 VS 2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020-2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2020-2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2020 VS 2024 VS 2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2020-2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2020-2031)
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Type Introduction
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Application
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Application Introduction
- Ovarian Cancer
- Breast Cancer
- Other
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2020 VS 2024 VS 2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2020-2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2020-2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2020 VS 2024 VS 2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2020-2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2020-2031)
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Application Introduction
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2020 VS 2024 VS 2031
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2020-2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2020-2025)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecasted by Region (2025-2030)
- North America
- North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2031)
- U.S.
- Canada
- Mexico
- Europe
- Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2031)
- Germany
- France
- U.K.
- Italy
- Netherlands
- Asia Pacific
- Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2031)
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- South America, Middle East and Africa
- South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2031)
- Brazil
- South Africa
- Saudi Arabia
- Turkey
- Argentina
- UAE
- Egypt
- Chile
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region: 2020 VS 2024 VS 2031
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2020-2025)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2026-2031)
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2020-2031)
- North America
- North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2020-2031)
- North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
- Europe
- Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2020-2031)
- Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
- Asia-Pacific
- Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2020-2031)
- Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
- South America, Middle East and Africa
- South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2020-2031)
- South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
- Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region
- Company Profiles
- AstraZeneca
- AstraZeneca Comapny Information
- AstraZeneca Business Overview
- AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- AstraZeneca Recent Developments
- Tesaro
- Tesaro Comapny Information
- Tesaro Business Overview
- Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- Tesaro Recent Developments
- Merck & Co
- Merck & Co Comapny Information
- Merck & Co Business Overview
- Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- Merck & Co Recent Developments
- Clovis Oncology
- Clovis Oncology Comapny Information
- Clovis Oncology Business Overview
- Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- Clovis Oncology Recent Developments
- Pfizer
- Pfizer Comapny Information
- Pfizer Business Overview
- Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- Pfizer Recent Developments
- GSK
- GSK Comapny Information
- GSK Business Overview
- GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- GSK Recent Developments
- Zai Lab
- Zai Lab Comapny Information
- Zai Lab Business Overview
- Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
- Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio
- Zai Lab Recent Developments
- AstraZeneca
- Value Chain and Sales Channels Analysis
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain Analysis
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Raw Materials
- Raw Materials Key Suppliers
- Manufacturing Cost Structure
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Mode & Process
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Channels Analysis
- Direct Comparison with Distribution Share
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain Analysis
- Concluding Insights
- Appendix
- Reasons for Doing This Study
- Research Methodology
- Research Process
- Authors List of This Report
- Data Source
- Secondary Sources
- Primary Sources
- Disclaimer
List of Tables
Table 1 | :PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Trends |
Table 2 | :PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Drivers |
Table 3 | :PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Opportunities and Challenges |
Table 4 | :PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Restraints |
Table 5 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers (US$ Million) & (2020-2025) |
Table 6 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Manufacturers (2020-2025) |
Table 7 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers (K Units) & (2020-2025) |
Table 8 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers |
Table 9 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Sales Price (USD/Unit) of Manufacturers (2020-2025) |
Table 10 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Industry Manufacturers Ranking, 2023 VS 2024 VS 2025 |
Table 11 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Key Manufacturers Manufacturing Sites & Headquarters |
Table 12 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers, Product Type & Application |
Table 13 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Establishment Date |
Table 14 | :Global Manufacturers Market Concentration Ratio (CR5 and HHI) |
Table 15 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2024) |
Table 16 | :Major Manufacturers of Lynparza |
Table 17 | :Major Manufacturers of Zejula |
Table 18 | :Major Manufacturers of Rubraca |
Table 19 | :Major Manufacturers of Talzenna |
Table 20 | :Major Manufacturers of Other |
Table 21 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type 2020 VS 2024 VS 2031 (K Units) |
Table 22 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020-2025) & (K Units) |
Table 23 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2026-2031) & (K Units) |
Table 24 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2020-2025) |
Table 25 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2026-2031) |
Table 26 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type 2020 VS 2024 VS 2031 (K Units) |
Table 27 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2020-2025) & (K Units) |
Table 28 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2026-2031) & (K Units) |
Table 29 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2020-2025) |
Table 30 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2026-2031) |
Table 31 | :Major Manufacturers of Ovarian Cancer |
Table 32 | :Major Manufacturers of Breast Cancer |
Table 33 | :Major Manufacturers of Other |
Table 34 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application 2020 VS 2024 VS 2031 (K Units) |
Table 35 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2020-2025) & (K Units) |
Table 36 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2026-2031) & (K Units) |
Table 37 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2020-2025) |
Table 38 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2026-2031) |
Table 39 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application 2020 VS 2024 VS 2031 (K Units) |
Table 40 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2020-2025) & (K Units) |
Table 41 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2026-2031) & (K Units) |
Table 42 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2020-2025) |
Table 43 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2026-2031) |
Table 44 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region: 2020 VS 2024 VS 2031 (K Units) |
Table 45 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Region (2020-2025) & (K Units) |
Table 46 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Region (2020-2025) |
Table 47 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecasted by Region (2026-2031) & (K Units) |
Table 48 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecasted Market Share by Region (2026-2031) |
Table 49 | :North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031 (K Units) |
Table 50 | :North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2025) & (K Units) |
Table 51 | :North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2026-2031) & (K Units) |
Table 52 | :Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031 (K Units) |
Table 53 | :Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2025) & (K Units) |
Table 54 | :Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2026-2031) & (K Units) |
Table 55 | :Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031 (K Units) |
Table 56 | :Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2025) & (K Units) |
Table 57 | :Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2026-2031) & (K Units) |
Table 58 | :South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031 (K Units) |
Table 59 | :South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2020-2025) & (K Units) |
Table 60 | :South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2026-2031) & (K Units) |
Table 61 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Table 62 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2020-2025) & (US$ Million) |
Table 63 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Region (2026-2031) & (US$ Million) |
Table 64 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2020-2025) |
Table 65 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region (2026-2031) |
Table 66 | :AstraZeneca Company Information |
Table 67 | :AstraZeneca Business Overview |
Table 68 | :AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 69 | :AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio |
Table 70 | :AstraZeneca Recent Development |
Table 71 | :Tesaro Company Information |
Table 72 | :Tesaro Business Overview |
Table 73 | :Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 74 | :Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio |
Table 75 | :Tesaro Recent Development |
Table 76 | :Merck & Co Company Information |
Table 77 | :Merck & Co Business Overview |
Table 78 | :Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 79 | :Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio |
Table 80 | :Merck & Co Recent Development |
Table 81 | :Clovis Oncology Company Information |
Table 82 | :Clovis Oncology Business Overview |
Table 83 | :Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 84 | :Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio |
Table 85 | :Clovis Oncology Recent Development |
Table 86 | :Pfizer Company Information |
Table 87 | :Pfizer Business Overview |
Table 88 | :Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 89 | :Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio |
Table 90 | :Pfizer Recent Development |
Table 91 | :GSK Company Information |
Table 92 | :GSK Business Overview |
Table 93 | :GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 94 | :GSK PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio |
Table 95 | :GSK Recent Development |
Table 96 | :Zai Lab Company Information |
Table 97 | :Zai Lab Business Overview |
Table 98 | :Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 99 | :Zai Lab PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Portfolio |
Table 100 | :Zai Lab Recent Development |
Table 101 | :Key Raw Materials |
Table 102 | :Raw Materials Key Suppliers |
Table 103 | :PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List |
Table 104 | :PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers List |
Table 105 | :Research Programs/Design for This Report |
Table 106 | :Authors List of This Report |
Table 107 | :Secondary Sources |
Table 108 | :Primary Sources |
List of Figures
Figure 1 | :PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Image |
Figure 2 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (US$ Million), 2020 VS 2024 VS 2031 |
Figure 3 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size (2020-2031) & (US$ Million) |
Figure 4 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (2020-2031) & (K Units) |
Figure 5 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Average Price (USD/Unit) & (2020-2031) |
Figure 6 | :Global Top 5 and 10 PARP (Poly ADP-Ribose Polymerase) Inhibitor Players Market Share by Revenue in 2023 |
Figure 7 | :Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023 |
Figure 8 | :Lynparza Image |
Figure 9 | :Zejula Image |
Figure 10 | :Rubraca Image |
Figure 11 | :Talzenna Image |
Figure 12 | :Other Image |
Figure 13 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2020 VS 2024 VS 2031) & (K Units) |
Figure 14 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share 2020 VS 2024 VS 2031 |
Figure 15 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2020-2031) |
Figure 16 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2020 VS 2024 VS 2031) & (K Units) |
Figure 17 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share 2020 VS 2024 VS 2031 |
Figure 18 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2020-2031) |
Figure 19 | :Ovarian Cancer Image |
Figure 20 | :Breast Cancer Image |
Figure 21 | :Other Image |
Figure 22 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2020 VS 2024 VS 2031) & (K Units) |
Figure 23 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share 2020 VS 2024 VS 2031 |
Figure 24 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2020-2031) |
Figure 25 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Application (2020 VS 2024 VS 2031) & (K Units) |
Figure 26 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share 2020 VS 2024 VS 2031 |
Figure 27 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Application (2020-2031) |
Figure 28 | :North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 29 | :North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2020-2031) |
Figure 30 | :U.S. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 31 | :Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 32 | :Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 33 | :Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 34 | :Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2020-2031) |
Figure 35 | :Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 36 | :France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 37 | :U.K. PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 38 | :Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 39 | :Netherlands PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 40 | :Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 41 | :Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2020-2031) |
Figure 42 | :China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 43 | :Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 44 | :South Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 45 | :Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 46 | :India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 47 | :Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 48 | :South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 49 | :South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2020-2031) |
Figure 50 | :Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 51 | :South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 52 | :Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 53 | :Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 54 | :Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 55 | :UAE PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 56 | :Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 57 | :Chile PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2020-2031) & (K Units) |
Figure 58 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Figure 59 | :Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Region in Percentage: 2023 Versus 2030 |
Figure 60 | :North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2020-2031) & (US$ Million) |
Figure 61 | :North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031 |
Figure 62 | :Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2020-2031) & (US$ Million) |
Figure 63 | :Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031 |
Figure 64 | :Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2020-2031) & (US$ Million) |
Figure 65 | :Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031 |
Figure 66 | :South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue (2020-2031) & (US$ Million) |
Figure 67 | :South America, Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031 |
Figure 68 | :PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain |
Figure 69 | :Manufacturing Cost Structure |
Figure 70 | :PARP (Poly ADP-Ribose Polymerase) Inhibitor Production Mode & Process |
Figure 71 | :Direct Comparison with Distribution Share |
Figure 72 | :Distributors Profiles |
Figure 73 | :Years Considered |
Figure 74 | :Research Process |
Figure 75 | :Key Executives Interviewed |
Request a Sample
Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Pharma & Healthcare
Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Pages: 181
Complete Your Request
Customer reviews
- 0 out of 5
- 0 Reviews
5
4
3
2
1
No Rating Review Exist.
Write Review
Suggested Report
View MoreNo data found.